Overactive Bladder in Women: an Update for Primary Care Physicians
- 8 Downloads
Purpose of Review
Overactive bladder (OAB) is a widely prevalent urinary condition affecting women of all ages, with increasing incidence in advancing age. A primary care provider is likely to encounter a significant proportion of women experiencing lower urinary tract symptoms (LUTS). This review serves primary care physicians as a thorough reference for a common condition causing LUTS in women.
Most emerging data addressing overactive bladder relates to the different treatment modalities available. The side effect profile of antimuscarinic drugs remains an ongoing concern among OAB patients, especially with recent data linking the use of this class of drugs with Alzheimer’s and future development of dementia. In addition, it was recently demonstrated that individuals taking medications of medium-to-high anticholinergic activity had reduced brain glucose metabolism and increased brain atrophy. Combination treatments seem to be more efficacious than monotherapies, as has been proven when using mirabegron with antimuscarinics. Many studies have also validated the use of neuromodulation as a safe and effective treatment for OAB.
Overactive bladder is a widely prevalent urinary condition affecting women of all ages. It is regarded as multifactorial with several proposed theories to explain its occurrence. Several tests are available to aid in diagnosing OAB. Symptom severity and patient-related factors including patient preferences drive treatment.
KeywordsOveractive bladder in females Lower urinary tract symptoms Detrusor instability Urinary incontinence
Compliance with Ethical Standards
The authors declare that they have no conflict of interest.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 24.Weiss JP, Blaivas JG. Nocturia. 2000;163(1):5–12.Google Scholar
- 30.Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn. 2005;24(3):215–25.PubMedCrossRefGoogle Scholar
- 38.Medicine, I.O. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate, vol. 638. Washington, DC: The National Academies Press; 2005.Google Scholar
- 43.Maserejian NN, Kupelian V, Miyasato G, McVary KT, McKinlay JB. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol. 2012;188(2):490–5.PubMedPubMedCentralCrossRefGoogle Scholar
- 57.Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003;92(7):741–7.PubMedCrossRefPubMedCentralGoogle Scholar
- 58.•• Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62 This recent case-control study demonstrates the robust association between the use of some anticholinergic medications and the future development of dementia. PubMedCrossRefPubMedCentralGoogle Scholar
- 59.•• Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33 This study demonstrated the in vivo brain strutural and functional effects of medications with medium-to-high anticholinergic activity. PubMedPubMedCentralGoogle Scholar
- 62.Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Initiative, association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults anticholinergic use, cognition, brain metabolism, and brain atrophy anticholinergic use, cognition, brain metabolism, and brain atrophy. JAMA Neurol. 2016;73(6):721–32.PubMedPubMedCentralCrossRefGoogle Scholar
- 65.•• Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–65 This recent meta-analysis showed the higher efficiacy of combination therapy: mirabegron and solifenacin. PubMedCrossRefGoogle Scholar
- 67.Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.PubMedCrossRefGoogle Scholar
- 68.Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33.PubMedCrossRefGoogle Scholar
- 74.Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20.PubMedPubMedCentralCrossRefGoogle Scholar
- 77.•• Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22 This prospective multicenter randomized trial demonstrated that sacral neuromodulation had superior therapeutic success compared with standard medical therapy among refractory patients with mild-to-moderate overactive bladder symptoms. PubMedCrossRefGoogle Scholar
- 78.•• Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56 This multicenter study shows the durability of sacral neuromodulation as a third-line treatment of overactive bladder on a 3-year follow-up. PubMedCrossRefGoogle Scholar
- 80.Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.PubMedCrossRefPubMedCentralGoogle Scholar
- 82.Adelstein SA, Lee W, Gioia K, Moskowitz D, Stamnes K, Lucioni A, et al. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique. 0(0).Google Scholar